Compare iShares MSCI Canada (TSX) (EWC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Twist Bioscience Corp — how do they compare? iShares MSCI Canada (TSX) trades at $59.51, while Twist Bioscience Corp trades at $91.48 (market cap $5.76B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.
| EWC | TWST | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.49 | $102.88 |
52-Week Low | $45.86 | $24.16 |
Market Cap | — | $5.76B |
Enterprise Value | — | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.38, up 0.34% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong momentum near key resistance at $60, supported by positive Canadian economic news including trade surpluses and nuclear energy expansion plans. A dividend of $0.28 is scheduled for June 2026, adding income appeal.
Outlook remains positive due to Canada's economic recovery and commodity strength, though risks include US trade policy uncertainty and high RSI levels suggesting near-term consolidation. Institutional sentiment is bullish, with technical support at $59 providing a floor for potential gains.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
